Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response

Dabska, 1969, Aneurysmal bone cyst: pathology, clinical course and radiologic appearances, Cancer, 23, 371, 10.1002/1097-0142(196902)23:2<371::AID-CNCR2820230213>3.0.CO;2-2 Rapp, 2012, Aneurysmal bone cyst, J Am Acad Orthop Surg, 20, 233, 10.5435/JAAOS-20-04-233 Mankin, 2005, Aneurysmal bone cyst: a review of 150 patients, J Clin Oncol, 23, 6756, 10.1200/JCO.2005.15.255 Cottalorda, 2005, Aneurysmal bone cysts of the pelvis in children: a multicenter study and literature review, J Pediatr Orthop, 25, 471, 10.1097/01.bpo.0000158002.30800.8f Leithner, 1999, Aneurysmal bone cyst: a population based epidemiologic study and literature review, Clin Orthop Rel Res, 363, 176, 10.1097/00003086-199906000-00023 Panoutsakopoulos, 1999, Recurrent t(16;17)(q22;p13) in aneurysmal bone cysts, Genes Chromosomes Cancer, 26, 265, 10.1002/(SICI)1098-2264(199911)26:3<265::AID-GCC12>3.0.CO;2-# Oliveira, 2004, USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts, Am J Pathol, 165, 1773, 10.1016/S0002-9440(10)63432-3 Gasbarrini, 2009, Management of benign tumors of the mobile spine, Orthop Clin North Am, 40, 9, 10.1016/j.ocl.2008.09.009 Ropper, 2011, Primary vertebral tumors: a review of epidemiologic, histological, and imaging findings, part I: benign tumors, Neurosurgery, 69, 1171, 10.1227/NEU.0b013e31822b8107 Thakur, 2012, Benign tumors of the spine, J Am Acad Orthop Surg, 20, 715, 10.5435/JAAOS-20-11-715 Papagelopoulos, 2001, Treatment of aneurysmal bone cysts of the pelvis and sacrum, J Bone Joint Surg Am, 83A, 1674, 10.2106/00004623-200111000-00009 Zileli, 2013, Aneurysmal bone cysts of the spine, Eur Spine J, 22, 593, 10.1007/s00586-012-2510-x Papagelopoulos, 1998, Aneurysmal bone cyst of the spine: management and outcome, Spine, 23, 621, 10.1097/00007632-199803010-00018 Rossi, 2012, Successful treatment of aggressive aneurysmal bone cyst of the pelvis with serial embolization, Orthopedics, 35, e963, 10.3928/01477447-20120525-43 Lacey, 1998, Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, 93, 165, 10.1016/S0092-8674(00)81569-X Yasuda, 1998, Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL, Proc Natl Acad Sci U S A, 95, 3597, 10.1073/pnas.95.7.3597 Hofbauer, 2004, Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases, JAMA, 292, 490, 10.1001/jama.292.4.490 Eghbali-Fatourechi, 2003, Role of RANK ligand in mediating increased bone resorption in early postmenopausal women, J Clin Invest, 111, 1221, 10.1172/JCI200317215 Bord, 2004, Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen, Br J Haematol, 126, 244, 10.1111/j.1365-2141.2004.05024.x Huang, 2000, Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation, Am J Pathol, 156, 761, 10.1016/S0002-9440(10)64942-5 Atkins, 2000, Expression of osteoclast differentiation signals by stromal elements of giant cell tumors, J Bone Miner Res, 15, 640, 10.1359/jbmr.2000.15.4.640 Roux, 2002, RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone, Am J Clin Pathol, 117, 210, 10.1309/BPET-F2PE-P2BD-J3P3 Morgan, 2005, Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB, Am J Pathol, 167, 117, 10.1016/S0002-9440(10)62959-8 Goldring, 1986, Characterization of cells from human giant cell tumors of bone, Clin Orthop Rel Res, 204, 59, 10.1097/00003086-198603000-00007 Takayanagi, 2002, Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts, Dev Cell, 3, 889, 10.1016/S1534-5807(02)00369-6 Branstetter, 2012, Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone, Clin Cancer Res, 18, 4415, 10.1158/1078-0432.CCR-12-0578 Thomas, 2010, Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study, Lancet Oncol, 11, 275, 10.1016/S1470-2045(10)70010-3 Won, 2011, RANK signalling in bone lesions with osteoclast-like giant cells, Pathology, 43, 318, 10.1097/PAT.0b013e3283463536 Kostenuik, 2009, Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL, J Bone Miner Res, 24, 182, 10.1359/jbmr.081112 Thomas, 2012, RANKL, denosumab, and giant cell tumor of bone, Curr Opin Oncol, 24, 397, 10.1097/CCO.0b013e328354c129 Bekker, 2004, A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women, J Bone Miner Res, 19, 1059, 10.1359/JBMR.040305 Rifkin, 2006, Denosumab in postmenopausal women with low bone mineral density, N Engl J Med, 354, 2390, 10.1056/NEJMc060819 Cummings, 2009, Denosumab for prevention of fractures in postmenopausal women with osteoporosis, N Engl J Med, 361, 756, 10.1056/NEJMoa0809493 Smith, 2009, Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer, J Urol, 182, 2670, 10.1016/j.juro.2009.08.048 Goessl, 2012, The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction, Ann N Y Acad Sci, 1263, 29, 10.1111/j.1749-6632.2012.06674.x Dempster, 2012, Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data, Clin Ther, 34, 521, 10.1016/j.clinthera.2012.02.002 Fizazi, 2009, Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates, J Clin Oncol, 27, 1564, 10.1200/JCO.2008.19.2146 Stopeck, 2010, Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study, J Clin Oncol, 28, 5132, 10.1200/JCO.2010.29.7101 Henry, 2011, Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma, J Clin Oncol, 29, 1125, 10.1200/JCO.2010.31.3304 Yee, 2012, Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients, Clin Interv Aging, 7, 331 Lipton, 2012, Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials, Eur J Cancer, 48, 3082, 10.1016/j.ejca.2012.08.002 Skubitz, 2004, Gene expression in giant-cell tumors, J Lab Clin Med, 144, 193, 10.1016/j.lab.2004.06.005 Fletcher, 2013 Liu, 2003, Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts, J Oral Pathol Med, 32, 367, 10.1034/j.1600-0714.2003.00126.x Taylor, 2012, CD14– mononuclear stromal cells support (CD14+) monocyte-osteoclast differentiation in aneurysmal bone cyst, Lab Invest, 92, 600, 10.1038/labinvest.2012.5 Peacock, 2008, Temporal and spatial expression of collagens during murine atrioventricular heart valve development and maintenance, Dev Dyn, 237, 3051, 10.1002/dvdy.21719 Oliveira, 2004, USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst, Cancer Res, 64, 1920, 10.1158/0008-5472.CAN-03-2827 Rossi, 2011, Selective arterial embolisation for bone tumours: experience of 454 cases, Radiol Med, 116, 793, 10.1007/s11547-011-0670-0 Ohashi, 2008, Percutaneous intralesional injection of calcitonin and methylprednisolone for treatment of an aneurysmal bone cyst at C-2, J Neurosurg Pediatr, 2, 365, 10.3171/PED.2008.2.11.365 George, 2009, Long-term follow-up of Ethibloc injection in aneurysmal bone cysts, J Pediatr Orthop B, 18, 375, 10.1097/BPB.0b013e32832f724c Turowski, 2005, Fatal Ethibloc embolization of vertebrobasilar system following percutaneous injection into aneurysmal bone cyst of the second cervical vertebra, AJNR Am J Neuroradiol, 26, 1883 Feigenberg, 2001, Megavoltage radiotherapy for aneurysmal bone cysts, Int J Radiat Oncol Biol Phys, 49, 1243, 10.1016/S0360-3016(00)01462-0 Chapurlat, 2012, Pathophysiology and medical treatment of pain in fibrous dysplasia of bone, Orphanet J Rare Dis, 7, S3, 10.1186/1750-1172-7-S1-S3 Cummings, 2010, Argon beam coagulation as adjuvant treatment after curettage of aneurysmal bone cysts: a preliminary study, Clin Orthop Rel Res, 468, 231, 10.1007/s11999-009-0914-7 Marcove, 1995, The treatment of aneurysmal bone cyst, Clin Orthop Rel Res, 311, 157 Brastianos, 2009, Aneurysmal bone cysts of the sacrum: a report of ten cases and review of the literature, Iowa Orthop J, 29, 74 Cottalorda, 2007, Modern concepts of primary aneurysmal bone cyst, Arch Orthop Trauma Surg, 127, 105, 10.1007/s00402-006-0223-5 Donati, 2011, Advance in the treatment of aneurysmal bone cyst of the sacrum, Skeletal Radiol, 40, 1461, 10.1007/s00256-011-1202-7 Thomas, 2010, Safety of denosumab in giant-cell tumour of bone, Lancet Oncol, 11, 815, 10.1016/S1470-2045(10)70170-4 Miller, 2011, A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis, Ther Adv Musculoskelet Dis, 3, 271, 10.1177/1759720X11424220 Silva-Fernandez, 2013, Denosumab for the treatment of osteoporosis: a systematic literature review, Rheumatol Clin, 9, 42 Kyrgidis, 2011, Denosumab-related osteonecrosis of the jaws, Osteoporos Int, 22, 369, 10.1007/s00198-010-1177-6 Boyce, 2012, Denosumab treatment for fibrous dysplasia, J Bone Miner Res, 27, 1462, 10.1002/jbmr.1603 Chakarun, 2013, Giant cell tumor of bone: review, mimics, and new developments in treatment, Radiographics, 33, 197, 10.1148/rg.331125089 Lange, 2013, Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts, Eur Spine J, 22, 1417, 10.1007/s00586-013-2715-7 Nakashima, 2012, New insights into osteoclastogenic signaling mechanisms, Trends Endocrinol Metab, 23, 582, 10.1016/j.tem.2012.05.005 Boyce, 2007, Biology of RANK, RANKL, and osteoprotegerin, Arthritis Res Ther, 9, S1, 10.1186/ar2165 Steiner, 1977, Ultrastructure of aneurysmal bone cyst, Cancer, 40, 2967, 10.1002/1097-0142(197712)40:6<2967::AID-CNCR2820400632>3.0.CO;2-I Aho, 1982, Aneurysmal bone cyst: a study of ultrastructure and malignant transformation, Virchow Arch A Pathol Anat Histol, 395, 169, 10.1007/BF00429610 Alles, 1986, Immunocytochemical markers (endothelial and histiocytic) and ultrastructure of primary aneurysmal bone cysts, Hum Pathol, 17, 39, 10.1016/S0046-8177(86)80153-8 Lipton, 2012, Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors, Expert Rev Clin Pharmacol, 5, 359, 10.1586/ecp.12.35 Fizazi, 2009, Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial, J Urol, 182, 509, 10.1016/j.juro.2009.04.023 Fizazi, 2011, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, Lancet, 377, 813, 10.1016/S0140-6736(10)62344-6